No, Checking Serum Estrogen Levels Before Starting Endocrine Therapy is Not Necessary
The decision to initiate endocrine therapy for breast cancer should be based on tumor estrogen receptor (ER) status determined by immunohistochemistry, not serum estrogen levels. The ASCO/CAP guideline explicitly states that ER testing of invasive breast cancers by validated immunohistochemistry is the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose 1.
Why Tumor ER Status, Not Serum Estrogen, Guides Treatment
The fundamental principle is straightforward: endocrine therapy targets the tumor's hormone receptor status, not circulating hormone levels. The 2020 ASCO/CAP guideline establishes that:
- Breast cancers with 1% to 100% of tumor nuclei ER-positive should receive endocrine therapy consideration 1
- Even tumors with ER-low expression (1%-10%) show survival benefit from endocrine therapy, particularly those with 6%-10% ER expression and residual disease after chemotherapy 2
- The mechanism of benefit relates to blocking estrogen signaling at the tumor receptor level, regardless of baseline serum estrogen concentrations
When Serum Estrogen Monitoring May Be Relevant (But Not Before Starting Therapy)
While baseline serum estrogen is not needed, monitoring during treatment is a separate consideration with limited evidence support:
In Premenopausal Women on Ovarian Suppression
- A 2025 survey found 43% of oncologists routinely and 27% occasionally check estradiol levels in premenopausal patients on LHRH agonists, but interpretation and management varied widely due to lack of standardized guidelines 3
- The clinical impact of incomplete ovarian suppression on outcomes remains unclear 3
- Standard immunoassays have considerable variability in methods and reference ranges, limiting reliability 3
In Postmenopausal Women on Aromatase Inhibitors
- Some evidence suggests estradiol can rebound during AI therapy in a subset of patients 4
- However, standard assays lack the sensitivity (requiring detection limits around 1 pM) to accurately measure the extremely low postmenopausal estrogen levels during potent AI treatment 5
Critical Pitfalls to Avoid
Do not delay or withhold endocrine therapy based on serum estrogen levels. The key errors include:
- Confusing tumor hormone receptor status (which predicts treatment benefit) with circulating hormone levels (which do not)
- Ordering unnecessary baseline estrogen testing that adds cost without clinical benefit
- Misinterpreting normal premenopausal estrogen levels as a contraindication to endocrine therapy (premenopausal women receive ovarian suppression plus endocrine therapy)
The Evidence Hierarchy
The guideline evidence 1 takes clear precedence here, establishing immunohistochemistry for tumor ER status as the sole recommended test for treatment decisions. The research on serum estrogen monitoring 3, 4 addresses a different question—treatment monitoring rather than treatment initiation—and even for monitoring, the evidence remains insufficient to support routine practice.
Bottom line: Check tumor ER status by immunohistochemistry. If ER-positive (≥1%), consider endocrine therapy. Serum estrogen levels are irrelevant to this decision.